Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE

Mira Mousa; Mohammed Albreiki; Fatima Alshehhi; Safiya AlShamsi; Nada Al Marzouqi; Tayba Alawadi; Hussain Alrand; Habiba Alsafar; Asma Fikri

doi:10.1093/jtm/taac036

Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE

J Travel Med. 2022 Sep 17;29(6):taac036. doi: 10.1093/jtm/taac036.

Authors

Mira Mousa^{1

2}, Mohammed Albreiki¹, Fatima Alshehhi³, Safiya AlShamsi⁴, Nada Al Marzouqi³, Tayba Alawadi³, Hussain Alrand³, Habiba Alsafar^{1

5

6

7}, Asma Fikri^{3

8}

Affiliations

¹ Center for Biotechnology, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, UAE.
² Nuffield Department of Women's and Reproduction Health, University of Oxford, Oxford OX3 9DU, UK.
³ Public Health Sector, Ministry of Health and Prevention, P.O. Box 1853, Dubai, UAE.
⁴ Laboratory Department, Emirates Health Services Establishment, P.O. Box 2299, Dubai, UAE.
⁵ Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, UAE.
⁶ Department of Genetics and Molecular Biology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, UAE.
⁷ Emirates Bio-Research Center, Ministry of Interior, P.O. Box 389, Abu Dhabi, UAE.
⁸ National Center for Health Research, Ministry of Health and Prevention, P.O. Box 848, UAE.

Abstract

Inactivated vaccine BBIBP-CorV (Sinopharm; 95% (95%CI: 94%,97%)) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech; 98% (95%CI: 86%,99%)) demonstrated protection against COVID-19 related hospitalizations from the Delta (B.1.617.2) variant. Ongoing efforts are necessary to target vaccine hesitancy and promote booster shots for protection against severe COVID-19 disease and arising variants of concern.

Keywords: B.1.617.2; BBIBP-CorV; BNT162b2; COVID-19; Delta; SARS-CoV-2; vaccine effectiveness.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

BNT162 Vaccine
COVID-19* / prevention & control
Disease Outbreaks / prevention & control
Hospitalization
Humans
Vaccines, Inactivated
Vaccines, Synthetic
mRNA Vaccines

Substances

Vaccines, Inactivated
Vaccines, Synthetic
mRNA Vaccines
BNT162 Vaccine